Friday, October 16, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· May 11, 2026

Exodus Reports First Quarter 2026 Results

View original at globenewswire.com
“Exodus Movement, Inc. (NYSE American: EXOD) ("Exodus"), a leading self-custodial cryptocurrency platform, today announced its unaudited results for the first quarter ended March 31, 2026. ... Net loss $(32.1) [in USD millions for Q1 2026]”
Verbatim excerpt from the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Net loss in Q1 2026 was $32.1 million, compared to $12.9 million in Q1 2025, a 149% increase in losses year-over-year

    60% confidence

  • Exchange provider processed volume was $1.18 billion in Q1 2026, down 26% from Q4 2025

    60% confidence

  • Top assets traded in Q1 2026 were Bitcoin (29%), Tether TRX Network (14%), Tether ETH Network (11%), ETH (9%), and USDC ETH Network (7%) of volume

    60% confidence

  • Quarterly funded users were 1.4 million at end of Q1 2026, down 18% from 1.7 million as of December 31, 2025

    60% confidence

  • XO Swap's share of exchange volume has grown steadily since launch, reflecting demand for best-execution routing across liquidity sources

    60% confidence

  • B2B swap partners generated $257 million in Q1 2026 volume, representing 22% of the quarterly total exchange volume

    60% confidence

  • Monavate and Baanx are established providers of card and payments infrastructure, serving fintech, crypto, and enterprise clients worldwide

    60% confidence

  • Total digital assets, cash, and cash equivalents were $122.6 million as of March 31, 2026, including $42.8M Bitcoin, $3.9M Ether, and $74.4M cash, cash equivalents, and stablecoins

    60% confidence

  • Full-time equivalent team members were approximately 220 as of March 31, 2026, up 5 from December 31, 2025

    60% confidence

  • Exodus monthly active users were 1.5 million as of March 31, 2026, unchanged from December 31, 2025

    60% confidence

  • General and administrative expense was $15.5 million in Q1 2026, up 8% from $14.3 million in Q1 2025

    60% confidence

  • Loss on digital assets, net was $36.4 million in Q1 2026, compared to $28.8 million in Q1 2025, a 26% increase

    60% confidence

  • Average customer response time was less than 60 minutes in Q1 2026

    60% confidence

  • Technology, development and user support expense was $16.2 million in Q1 2026, up 9% from $14.9 million in Q1 2025

    60% confidence

  • Q1 2026 revenue was $22.7 million, down 37% from $36.0 million in Q1 2025

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com